Treatment of TTP-deficient mice with neutralizing anti-TNF-α antibodies results in alleviating most of the pathological features in TTP-deficient mice [27], demonstrating the involvement of TNF-α in the development of the pathological features in TTP-deficient mice. This evidence concerns the gene TNF and thrombotic thrombocytopenic purpura.